High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:18
|
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Preliminary report of a single-channel applicator in high dose rate afterloading brachytherapy for cervical cancer
    Li, Dan
    Wen, En
    Zhang, Yingjie
    Wu, Zhouxue
    Pang, Haowen
    Ren, Peirong
    Shang, Changling
    He, Lijia
    Zhang, Jianwen
    Xiang, Li
    Yang, Hongru
    Liu, Qiaoli
    Wen, Qinglian
    Fan, Juan
    Lin, Sheng
    Wu, Jingbo
    CANCER SCIENCE, 2018, 109 (12): : 3953 - 3961
  • [42] Pain in High-Dose-Rate Brachytherapy for Cervical Cancer: A Retrospective Cohort Study
    Becerra-Bolanos, Angel
    Jimenez-Gil, Miriam
    Federico, Mario
    Dominguez-Diaz, Yurena
    Valencia, Lucia
    Rodriguez-Perez, Aurelio
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08):
  • [43] Biological Planning for High-Dose-Rate Brachytherapy: Application to Cervical Cancer Treatment
    Lee, Eva K.
    Yuan, Fan
    Templeton, Alistair
    Yao, Rui
    Kiel, Krystyna
    Chu, James C. H.
    INTERFACES, 2013, 43 (05) : 462 - 476
  • [44] Brachytherapy guideline in prostate cancer (high and low dose rate)
    Hanna, Samir Abdallahah
    Pimentel, Leonardo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (04): : 293 - 298
  • [45] Radiobiological comparison between Cobalt-60 and Iridium-192 high-dose-rate brachytherapy sources: Part I-cervical cancer
    Dayyani, Mahdieh
    Hoseinian-Azghadi, Elie
    Miri-Hakimabad, Hashem
    Rafat-Motavalli, Laleh
    Abdollahi, Sara
    Mohammadi, Najmeh
    MEDICAL PHYSICS, 2021, 48 (10) : 6213 - 6225
  • [46] Pulse dose-rate brachytherapy and treatment of uterine cervix cancer:: impact of a 3D or a 2D dosimetric support
    Tournat, H.
    Chilles, A.
    Charra-Brunaud, C.
    Peiffert, D.
    Ahmad, F.
    Metayer, Y.
    CANCER RADIOTHERAPIE, 2007, 11 (04): : 188 - 196
  • [47] Improving dose delivery by adding interstitial catheters to fixed geometry applicators in high-dose-rate brachytherapy for cervical cancer
    Otter, Sophie
    Coates, Amanda
    Franklin, Adrian
    Cunningham, Melanie
    Stewart, Alexandra
    BRACHYTHERAPY, 2018, 17 (03) : 580 - 586
  • [48] After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
    Nakamura, Satoshi
    Murakami, Naoya
    Inaba, Koji
    Wakita, Akihisa
    Kobayashi, Kazuma
    Takahashi, Kana
    Okamoto, Hiroyuki
    Umezawa, Rei
    Morota, Madoka
    Sumi, Minako
    Igaki, Hiroshi
    Ito, Yoshinori
    Itami, Jun
    BMC CANCER, 2016, 16
  • [49] On the impact of improved dosimetric accuracy on head and neck high dose rate brachytherapy
    Peppa, Vasiliki
    Pappas, Eleftherios
    Major, Tibor
    Takacsi-Nagy, Zoltan
    Pantelis, Evaggelos
    Papagiannis, Panagiotis
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 (01) : 92 - 97
  • [50] Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer
    Williamson, Casey W.
    Kotha, Nikhil V.
    Zou, Jingjing
    Brown, Derek
    Scanderbeg, Daniel
    Rash, Dominique
    Einck, John
    Yashar, Catheryn
    Mell, Loren K.
    Mayadev, Jyoti
    BRACHYTHERAPY, 2023, 22 (03) : 317 - 324